Observational studyJournal of the American College of Cardiology2022
Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk.
Observational study in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 90 citations in OpenAlex.
- Temporal changes in lipoprotein(a) after acute coronary syndrome.American journal of preventive cardiology · 2027Article
- Identifying and resolving analytical outliers in lipoprotein(a) immunoassay testing.Practical laboratory medicine · 2026Article
- Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances.Atherosclerosis plus · 2026Article
- Substantial Change Between Repeated Lipoprotein(a) Measurements Is Associated with Residual Cardiovascular Risk in a Real-World Multicenter Cohort.Journal of clinical medicine · 2026Article
- Drivers of Atherosclerotic Cardiovascular Disease in South Asians: Current Insights and Future Directions.JACC. Asia · 2026Review
- Review
- Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study.Journal of clinical medicine · 2026Article
- Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome.Journal of clinical medicine · 2026Review
- Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a).Lipids in health and disease · 2026Article
- Lipoprotein(a) epidemiology and role in secondary and primary-and-a-half cardiovascular prevention: From subclinical atherosclerosis to coronary events.American journal of preventive cardiology · 2026Article
- Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target.Frontiers in medicine · 2026Review
- Proteomic analysis identifies lipoprotein(a)-associated proteins linked to incident atherosclerotic cardiovascular disease events.medRxiv : the preprint server for health sciences · 2025Article
- Association between lipoprotein(a) levels, cumulative lipoprotein(a) burden, and cardiovascular outcomes in patients with acute myocardial infarction: a large-scale cohort study.Lipids in health and disease · 2025Article
- Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study.Annals of medicine · 2025Article
- Reclassification of Low or Intermediate Cardiovascular Risk by Determining Lipoprotein(a) Levels.Biomedicines · 2025Article
- Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort.JACC. Basic to translational science · 2025Article
- Lipoprotein(a) at a "Tipping Point": case to move to universal screening.American journal of preventive cardiology · 2025Review
- Predictors of lipoprotein(a) variability in clinical practice and their impact on cardiovascular risk.Lipids in health and disease · 2025Observational
- Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches.Current cardiology reports · 2025Review
- Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution.Lipids in health and disease · 2025Article
Corrections and comments
- Commented on by
- Erratum issuedCorrection.2022
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundWhen indicated, guidelines recommend measurement of lipoprotein(a) for cardiovascular risk assessment. However, temporal variability in lipoprotein(a) is not well understood, and it is unclear if repeat testing may help refine risk prediction of coronary artery disease (CAD).
objectivesThe authors examined the stability of repeat lipoprotein(a) measurements and the association between instability in lipoprotein(a) molar concentration with incident CAD.
methodsThe authors assessed the correlation between baseline and first follow-up measurements of lipoprotein(a) in the UK Biobank (n = 16,017 unrelated individuals). The association between change in lipoprotein(a) molar concentration and incident CAD was assessed among 15,432 participants using Cox proportional hazards models.
resultsBaseline and follow-up lipoprotein(a) molar concentration were significantly correlated over a median of 4.42 years (IQR: 3.69-4.93 years; Spearman rho = 0.96; P < 0.0001). The correlation between baseline and follow-up lipoprotein(a) molar concentration were stable across time between measurements of <3 (rho = 0.96), 3-4 (rho = 0.97), 4-5 (rho = 0.96), and >5 years (rho = 0.96). Although there were negligible-to-modest associations between statin use and changes in lipoprotein(a) molar concentration, statin usage was associated with a significant increase in lipoprotein(a) among individuals with baseline levels ≥70 nmol/L. Follow-up lipoprotein(a) molar concentration was significantly associated with risk of incident CAD (HR per 120 nmol/L: 1.32 [95% CI: 1.16-1.50]; P = 0.0002). However, the delta between follow-up and baseline lipoprotein(a) molar concentration was not significantly associated with incident CAD independent of follow-up lipoprotein(a) (P = 0.98).
conclusionsThese findings suggest that, in the absence of therapies substantially altering lipoprotein(a), a single accurate measurement of lipoprotein(a) molar concentration is an efficient method to inform CAD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.